Targeted nanotherapy with everolimus reduces inflammation and fibrosis in scleroderma‐related interstitial lung disease developed by PSGL‐1 deficient mice. (13th July 2022)

• Record Type: Journal Article
• Authors: González‐Sánchez, Elena; Muñoz‐Callejas, Antonio; Gómez‐Román, Javier; San Antonio, Esther; Marengo, Alessandro; Tsapis, Nicolas; Bohne‐Japiassu, Kamila; González‐Tajuelo, Rafael; Pereda, Saray; García‐Pérez, Javier; Cavagna, Lorenzo; González‐Gay, Miguel Ángel; Vicente‐Rabaneda, Esther Francisca; Meloni, Federica; Fattal, Elias; Castañeda, Santos; Urzainqui, Ana
• Is Part Of: British journal of pharmacology. Volume 179:Number 18(2022)
• Page Start: 4534
• Page End: 4548
• Publication Date: 2022-07-13
• Subjects: everolimus -- interstitial lung disease -- nanotherapy -- PSGL‐1 -- systemic sclerosis; Pharmacology -- Periodicals; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1111/bph.15898
• Languages: English
• ISSNs: 0007-1188

Abstract

Abstract : Background and Purpose: Interstitial lung disease (ILD) is the main cause of mortality in systemic sclerosis (SSc), and current therapies available are of low efficacy or high toxicity. Thus, the identification of innovative less toxic and high efficacy therapeutic approaches to ILD treatment is an urgent need. The interaction of P‐selectin glycoprotein ligand‐1 (PSGL‐1) with P‐selectin initiates leukocyte extravasation and deletion of the corresponding gene ( Selplg ) induces a SSc‐like syndrome with high incidence of ILD in aged mice. Experimental Approach: Aged PSGL‐1 KO ( Selplg ‐/‐ ) mice were used to assess the therapeutic effects of nanotherapy with everolimus, included in liposomes decorated with high MW hyaluronic acid (LipHA+Ev) and administered intratracheally to specifically target CD44‐expressing lung cells. Key Results: PSGL‐1 KO mice had increased numbers of CD45+ and CD45− cells, including alveolar and interstitial macrophages, eosinophils, granulocytes and NK cells, and myofibroblasts in bronchoalveolar lavage (BAL). CD45+ and CD45− cells expressing pro‐inflammatory and pro‐fibrotic cytokines were also increased. Lungs from PSGL‐1 KO mice showed increased immune cell infiltration and apoptosis and exacerbated interstitial and peribronchial fibrosis. Targeted nanotherapy with LipHA+Ev decreased the myofibroblasts in BAL, cells producing proinflammatory and profibrotic cytokines, and the degree of lung inflammation at histology. LipHA+Ev treatment also decreased the severity of peribronchial and interstitial lung fibrosis, from moderate to mild levels. Conclusions and Implications: In PSGL‐1 KO mice, targeted nanotherapy with LipHA+Ev was an effective treatment for SSc‐ILD, reducing the number of inflammatory and fibrotic cells in BAL and reducing inflammation and fibrosis in lungs. Abstract :